Navigation Links
Nektar Therapeutics Reports Third Quarter 2009 Financial Results
Date:11/4/2009

tements at that date but does not include all of the information and notes required by generally accepted accounting principles in the United States for complete financial statements. NEKTAR THERAPEUTICS CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (In thousands) (unaudited) Nine Months Ended September 30, ----------------- 2009 2008 ---- ---- Cash flows from operating activities: $(94,843) $(111,118) Net loss Adjustments to reconcile net loss to net cash used in operating activities: Depreciation and amortization 11,076 18,610 Stock-based compensation 7,290 6,955 Other non-cash transactions (124) 759 Changes in assets and liabilities: Decrease (increase) in trade accounts receivable 4,505 13,122 Decrease (increase) in inventory 389 2,326 Decrease (increase) in other assets (1,272) 2,659 Increase (decrease) in accounts payable (4,047) (1,476) Increase (decrease) in accrued compensation (1,859) (229) Increase (decrease) in accrued clinical trial expenses (4,610) 4,659 Increase (decrease) in accrued expenses (1,413) (1,390) Increase (decrease) in accrued expenses to contract manufacturers
'/>"/>
SOURCE Nektar Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Nektar to Announce Financial Results for the Third Quarter of 2009 on Wednesday, November 4, 2009, After Close of U.S.-Based Financial Markets
2. Nektar Therapeutics to Host Conference Call to Discuss Todays Announcement of a New Partnership for NKTR-118 and NKTR-119
3. AstraZeneca and Nektar Sign Worldwide Agreement for Nektar Drug Development Programmes -- NKTR-118 and NKTR-119 -- to Address Opioid-Induced Constipation
4. Nektar Therapeutics to Present at the BMO Capital Markets 9th Annual Focus on Healthcare Conference in New York City
5. Nektar to Announce Financial Results for the Second Quarter of 2009 on Tuesday, August 4, 2009, After Close of U.S.-Based Financial Markets
6. Nektar Therapeutics Promotes Lorianne Masuoka, M.D. to Chief Medical Officer
7. Nektar Therapeutics Reports First Quarter 2009 Financial Results
8. Nektar Therapeutics President and CEO, Howard W. Robin, to Present at the 29th Annual Cowen and Company Healthcare Conference in Boston
9. Nektar Therapeutics Reports Fourth Quarter and Year-End 2008 Financial Results
10. Nektar to Announce Year-End 2008 Financial Results on Wednesday, February 25, 2009 After Close of U.S.-Based Financial Markets
11. Nektar Announces Retirement of Irwin Lerner from Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/6/2015)... LOS ANGELES , July 6, 2015 ... the establishment of an agreement with Novella Clinical ... of ICT-107 in patients with newly diagnosed glioblastoma. Novella ... clinical trial services to small to mid-sized oncology companies. ... clinical sites in the US, Europe ...
(Date:7/3/2015)... ... ... The global failure analysis market is expected to reach $7,147.0 million by 2020, ... to grow at the highest CAGR of 8.46%; its growth is expected to be ... academic institutions for root cause analysis of failure. The market based on the geographic ...
(Date:7/2/2015)... ... ... in countless labs for decades. In the past, people had to go to a ... a daunting and tiring process looking at endless data tables and charts. Often time’s, ... catalog structure. , Now thanks to FireflySci, scientists are throwing away those old books and ...
(Date:7/2/2015)... TN (PRWEB) , ... July 02, 2015 , ... ... the development and manufacturing of surgical instruments in Orthopedics, announced today the acquisition ... contract-manufacturing and the world's largest provider of surgical instruments to the Spine Industry. ...
Breaking Biology Technology:ImmunoCellular Therapeutics Establishes Agreement with Novella Clinical to Conduct ICT-107 Phase 3 Registration Trial in Glioblastoma 2Failure Analysis Market to Grow at 7.52% CAGR to 2020 2Failure Analysis Market to Grow at 7.52% CAGR to 2020 3Failure Analysis Market to Grow at 7.52% CAGR to 2020 4Failure Analysis Market to Grow at 7.52% CAGR to 2020 5New Cuvette E-Commerce Website Launched by FireflySci 2In'Tech Medical Acquires Turner Medical to Become a World Leader in Orthopedic Contract-Manufacturing 2In'Tech Medical Acquires Turner Medical to Become a World Leader in Orthopedic Contract-Manufacturing 3
... and SAN FRANCISCO, Nov. 8, 2011 Boston ... positive long-term data from the PERSEUS clinical program, ... for the ION™ (TAXUS Element) Paclitaxel-Eluting Platinum Chromium ... presented today by PERSEUS clinical program Principal Investigators ...
... 8, 2011 ACCESS PHARMACEUTICALS, INC. (OTCBB: ... drug-delivery platforms to develop treatments in areas of oncology, ... has entered into an agreement with a major player ... technology for the targeted delivery of RNAi therapeutics.  Access ...
... IDEXX Laboratories, Inc. (NASDAQ: IDXX ... research and diagnostic laboratory (RADIL) business of the ... Missouri for $43 million in cash. Based in ... testing services to bioresearch customers. ...
Cached Biology Technology:Boston Scientific Platinum Chromium ION™ Stent Demonstrates Positive Outcomes in PERSEUS Clinical Program 2Boston Scientific Platinum Chromium ION™ Stent Demonstrates Positive Outcomes in PERSEUS Clinical Program 3Boston Scientific Platinum Chromium ION™ Stent Demonstrates Positive Outcomes in PERSEUS Clinical Program 4Boston Scientific Platinum Chromium ION™ Stent Demonstrates Positive Outcomes in PERSEUS Clinical Program 5Access Pharmaceuticals Signs Agreement for CobaCyte® and CobOral® in RNAi Therapeutic Delivery 2Access Pharmaceuticals Signs Agreement for CobaCyte® and CobOral® in RNAi Therapeutic Delivery 3IDEXX Laboratories Acquires the RADIL Reference Laboratory from the University of Missouri 2IDEXX Laboratories Acquires the RADIL Reference Laboratory from the University of Missouri 3IDEXX Laboratories Acquires the RADIL Reference Laboratory from the University of Missouri 4
(Date:6/24/2015)... -- This report provides market analysis of the Automatic ... contains an analysis of the drivers, challenges, and restraints ... the short, medium, and long term perspective landscapes. ... technology trends that currently, prevail in the market. It ... efficiently manage the increasing marine traffic and increasing importance ...
(Date:6/24/2015)... , June 24, 2015 Biometry authentication ... emerging biometric password solution one face in. ... one face in, entering the expanding ... and affordable multifactor-authentication biometric answer to the password ... provided in partnership with KeyLemon, one face in ...
(Date:6/23/2015)... , June 23, 2015   Valencell, ... the results of a recent study that illustrates ... the wrist during activity. In a study conducted ... compared along with the Apple Watch against a ... heart rate during activity. The study demonstrated that ...
Breaking Biology News(10 mins):Automatic Identification System Market by Class, by Platform, by Application and by Geography - Global Forecasts & Analysis to 2014 - 2020 2KeyLemon Announces Partnership With Biometric Password Solution onefacein 2Valencell Delivers Breakthrough Heart Rate Accuracy on the Wrist 2Valencell Delivers Breakthrough Heart Rate Accuracy on the Wrist 3
... have an overall positive impact on wild salmon populations ... of Southampton. Representatives of recreational fisheries interests north ... can harm economically important fish stocks due to their ... phases. However, results of a study conducted by ...
... the inner ear via anterior extensions of the swim ... explains how swim bladders may serve for hearing. The ... part of the swim bladder functions in specialized fish ... the effects of the different swim bladder morphologies have ...
... large and growing problem throughout the developed world, and ... the recalcitrant bacteria. When bacteria aggregate into so-called biofilm, ... only been able to speculate about what happens when ... In close collaboration between various specialist fields, ...
Cached Biology News:Do beavers benefit Scottish wild salmon? 2Do beavers benefit Scottish wild salmon? 3Cichlid fish: How does the swim bladder affect hearing? 2New scientific method unmasks chronic infections 2
... Accurate To score SNPs, ... sequencing, the gold standard in DNA analysis. ... The polymorphic locus can be confirmed by ... DNA sequencing also provides sequence context information, ...
... 96 and PowerPac basic power supply are used ... in agarose gels. This Model 96 cell includes ... UV-transparent gel tray with fluorescent ruler, and a ... and 220-240 V, provides output of 10-300 V, ...
... mini ReadySub-Cell GT cell and PowerPac basic power ... of nucleic acids in agarose gels. The mini ... cables and electrodes, and leveling bubble. The PowerPac ... output of 10-300 V, 4-400 mA, and 75 ...
... ReadySub-Cell GT cell and PowerPac basic power supply ... nucleic acids in agarose gels. The wide mini ... cables and electrodes, and leveling bubble. The PowerPac ... output of 10-300 V, 4-400 mA, and 75 ...
Biology Products: